Shots:
- Bio-Thera Solutions has entered into an exclusive commercialization & license agreement with Intas Pharmaceuticals for BAT2506, a biosimilar version of Simponi (golimumab), for Canada
- The agreement expands their Feb 2025 deal, under which Intas holds US commercialization rights for BAT2506, while Bio-Thera handles its development & manufacturing
- BAT2506 is an IgG1 monoclonal antibody that targets TNF-alpha, resulting in the decrease of inflammatory markers like CRP, IL-6, ICAM-1, MMP-3, & VEGF for treating chronic inflammatory & immune-mediated diseases
Ref: Bio-Thera | Image: Bio-Thera and Intas Pharmaceuticals | Press Release
Related News:- Bio-Thera Solutions Collaborates with Jamjoom Pharmaceuticals to Commercialize BAT2306 (Biosimilar, Cosentyx)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
